AI has moved out of the experimental phase in healthcare. It is no longer something teams are exploring on the side. It is now embedded in how organizations think about patient engagement, communication, and scale. But as adoption accelerates, something more subtle is happening beneath the surface. Patients are not just receiving more information. They […]
Read more
Over the past week, one thing has become increasingly clear. Artificial intelligence is no longer sitting on the sidelines of pharma. It is actively reshaping how drugs are discovered, how trials are run, and how quickly therapies move through regulatory pathways. The FDA is now preparing to expand its use of generative AI to accelerate […]
Read more
Today we released a press announcement that addresses something pharma leaders already feel in their forecasts, but rarely quantify directly: Patient dropout is quietly draining $250 billion from the U.S. pharmaceutical market every year. You can read the full announcement here:https://www.prnewswire.com/news-releases/pharma-is-losing-250-billion-to-patient-dropout-heres-how-to-stop-it-302696178.html Not because therapies do not work. Not because innovation has slowed. But because patients […]
Read more